Sunil Mathur
Overview
Explore the profile of Sunil Mathur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goel P, Katsumata M, Qian W, Mathur S, Ji M, Samanta A, et al.
Breast Cancer (Dove Med Press)
. 2024 Nov;
16:725-733.
PMID: 39493351
Background: Breast cancer predominantly affects women and poses challenges in the treatment of both local and advanced diseases. In a previous study, we reported the effectiveness of ER121, a structurally...
2.
Shao J, Xu Y, Olsen R, Kasparian S, Sun K, Mathur S, et al.
Cells
. 2024 Apr;
13(8.
PMID: 38667328
Immune checkpoint inhibitors (ICIs) drastically improve therapeutic outcomes for lung cancer, but accurately predicting individual patient responses to ICIs remains a challenge. We performed the genome-wide profiling of 5-hydroxymethylcytosine (5hmC)...
3.
Burns E, Chen W, Mathur S, Kieser R, Zhang J, Bernicker E
JTO Clin Res Rep
. 2023 Oct;
4(10):100570.
PMID: 37822698
Introduction: The aim of this study is to evaluate treatment patterns, survival outcomes, and factors influencing systemic treatment decisions in adults 80 years and older with NSCLC. Methods: This was...
4.
Guan J, Sun K, Guerrero C, Zheng J, Xu Y, Mathur S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
118(5):1531-1540.
PMID: 37625523
Purpose: A phase 2 study of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy in metastatic non-small cell lung cancer (mNSCLC) followed by pembrolizumab (STOMP) was designed...
5.
Burns E, Wilson J, Mathur S, Kieser R, Gong Z, Hu C, et al.
Ann Hematol
. 2023 Jul;
102(10):2753-2763.
PMID: 37422592
Burkitt lymphoma (BL) is an extremely aggressive but curable subtype of non-Hodgkin lymphoma. While younger patients have excellent outcomes in response to aggressive chemoimmunotherapy, the rarity of this disease in...
6.
Burns E, Gentille Sanchez C, Mathur S, Guerrero C, Muhsen I, Sarfraz H, et al.
Ann Hematol
. 2023 Mar;
102(5):1111-1120.
PMID: 36922432
Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-Hodgkin lymphoma that carries a poor prognosis in the elderly. The aim of this study is to investigate treatment...
7.
Sun K, Xu Y, Zhang L, Niravath P, Darcourt J, Patel T, et al.
Clin Cancer Res
. 2022 Jul;
28(20):4392-4401.
PMID: 35877117
Purpose: A Phase 2 trial of stereotactic radiotherapy and in situ cytotoxic virus therapy in patients with metastatic triple-negative breast cancer (mTNBC) followed by pembrolizumab (STOMP) was designed to evaluate...
8.
Bustos F, Mathur S, Espejo-Serrano C, Toth R, Hastie C, Virdee S, et al.
Life Sci Alliance
. 2022 Jun;
5(11).
PMID: 35764390
Ubiquitylation enzymes are involved in all aspects of eukaryotic biology and are frequently disrupted in disease. One example is the E3 ubiquitin ligase RNF12/RLIM, which is mutated in the developmental...
9.
Maxwell A, Kent A, Tinkler M, Mathur S, Beale A
Thorax
. 2020 Oct;
76(7):740-741.
PMID: 33115938
No abstract available.
10.
Mathur S, Fletcher A, Branigan E, Hay R, Virdee S
Cell Chem Biol
. 2019 Dec;
27(1):74-82.e6.
PMID: 31859248
Activity-based protein profiling is an invaluable technique for studying enzyme biology and facilitating the development of therapeutics. Ubiquitin E3 ligases (E3s) are one of the largest enzyme families and regulate...